Stereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference
November 22 2019 - 09:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announced
today its Chairman and Chief Executive Officer, David Fischel, will
present at the 12th annual BIOMEDevice San Jose conference.
BIOMEDevice San Jose is a two-day educational
program focused on the expansion of digital technology in the field
of healthcare, gathering top medical device innovators, experts,
and physicians to discuss the role of digital medicine in
revolutionizing the healthcare industry. It will take place at the
San Jose Convention Center on December 4-5, 2019. Mr. Fischel will
be a panelist in a session entitled, What’s Next for Robotic
Surgery? on December 5, 2019 at 1:35 p.m. PST. The session will
address the fast-moving surgical robotics landscape and the
dominant innovations and trends for the coming decade.
“We are excited to join BIOMEDevice to explore
the future of robotic surgery and the role our technology can play
in positively transforming interventional medicine. I am honored to
participate in this program alongside many industry experts and
innovators and look forward to being part of the event,” Mr.
Fischel said.
About BIOMEDeviceBIOMEDevice
San Jose is a must-attend event for medtech professionals looking
to learn, share, and discuss significant trends, latest
developments, and key technologies that are moving the medtech
industry forward. The program will highlight sectors ranging from
digital health to in vitro diagnostics and delve into cutting-edge
technologies that are revolutionizing medical devices. The program
will also focus on the latest in minimally invasive surgery and the
expansion of surgical robotics.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company
Contacts:
David
L. FischelChairman and Chief Executive Officer
Kimberly R.
Peery
Chief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2023 to Mar 2024